Predictive value of naitfold capillaroscopy in patients with Raynaud's phenomenon by Meli, Madeleine et al.
Clin Rheumatol (2006) 25:153-158 
DOI 10.1007/s10067-005-1146-1 
Madeleine Meli  • Gabriela Gitzeimann 
Renate Koppensteiner - Beatrice R. Amann-Vesti 
Predictive value of naUfold capiUaroscopy in patients 
with Raynaud's phenomenon 
Received: 16 November 2004/ Revised: 23 March 2005/Accepted: 23 March 2005/Published online: 11 June 2005 
© Clinical Rheumatology 2005 
Abstract The objective of this study was to evaluate 
the long-term follow-up of patients with Raynaud's 
phenomenon (RP) and pathological nailfold capilla- 
roscopy (NC) in order to analyse the predictive value 
of specific features of capillaroscopy for the develop- 
ment of a connective tissue disease (CTD). From 1992 
to 2002, NC alone or combined with fluorescence vid- 
eomicroscopy with sodium fluorescein (NaF) was per- 
formed in 1024 consecutive patients because of RP. We 
analysed the follow-up and pathological features of NC 
in all patients who had neither clinical nor serological 
signs of a CTD at the time of NC. Of 308 patients with 
neither serological findings nor clinical signs of CTD 
but with RP and pathological features in NC suspi- 
cious for CTD, follow-up data were available for 133 
patients. An additional NaF test had been performed 
in 51 (38.4%) patients. After a mean follow-up of 
6.5 years (range: 1-15 years), 109 patients had devel- 
oped a CTD and 24 patients did not show any clinical 
signs or serological markers for a CTD after a mean 
follow-up of 8.5 years (range: 2-15 years). There were 
no differences in age, duration of RP or of follow-up in 
patients who developed a CTD compared to patients 
who did not. Significantly more giant capillaries 
(p = 0.0001), avascular fields (p=0.02) and irregular 
architecture (/9=0.0001) had been observed in patients 
who had developed a CTD during the follow-up of 
6.5 years. The presence of giant capillaries, avascular 
fields and irregular architecture of nailfold capillaries is 
predictive for the development of a CTD in patients 
with RP. 
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Introduction 
Raynaud's phenomenon (RP) is classified as primary 
when no underlying cause can be identified and as sec- 
ondary when its presence is explained by an associated 
condition such as systemic lupus erythematosus (SLE) 
and systemic sclerosis. Estimates of the prevalence of RP 
in the general population range from 5 to 20% [1], and 
3-5% have been reported to develop a connective tissue 
disease (CTD) within 3-6 years [2]. In scleroderma, RP 
has been reported to be the presenting sign in 50-70% of 
patients and in 15% of patients with SLE [3-5]. How- 
ever, RP may precede the development of the disease by 
many years. In several small studies it has been reported 
that the presence of autoantibodies may predict the 
presence or future development of systemic disease [6-8]. 
Nailfold capillaroscopy (NC) allows the in vivo 
assessment of morphology and of some functional as- 
pects of cutaneous capillaries and has been accepted as a 
diagnostic tool for evaluating microvascular involvement 
in systemic sclerosis, dermatomyositis, overlap syn- 
dromes and SLE [9-12]. Only little is known about the 
role of NC in identifying patients with RP who are at risk 
of developing a CTD [13-15]. Furthermore, by fluores- 
cence videomicroscopy with sodium fluorescein (NaF) 
patients with a CTD might exhibit halo enlargement with 
a typical "dwarf hat" formation as a sign of disturbed 
barrier function of the vessel wall and structural changes 
of the pericapillary space [16]. However, it has been 
shown in one study that of 69 patients with CTD 16% 
had normal findings in conventional NC but pathologi- 
cal halo formation after NaF injection [17]. The predic- 
tive value of combined NC with NaF has not been 
studied yet. In the present report, we describe the follow- 
up of 133 patients with pathological findings in NC with 
154 
or without NaF  who were referred to our clinic because 
of  RP. At the time of  the study, all patients had negative 
autoantibodies and no other clinical signs of  a CTD. 
Patients and methods 
In the period from 1992 to 2002, 1024 patients were re- 
ferred to our institution for vascular assessment includ- 
ing NC because of  a history of  RP of  the hands and 
fingers. In all patients NC was performed; fluorescence 
videomicroscopy with NaF  was only performed in part 
of the patients. Exclusion criteria for NaF  were drug or 
food allergies, history of  renal disease, pathological cre- 
atinine clearance, and pregnancy. In some cases the NaF 
test was not performed because of difficulties in punc- 
turing a vein or no specific reason was given. Fluores- 
cence videomicroscopy with NaF  was performed as 
previously described [18]. NC was performed with a 
fluorescence videomicroscopy system consisting of an 
incident light fluorescence microscope (Leica, Heerb- 
rugg, Switzerland), a 3-CCD video camera (model DXC- 
930P, Sony, Tokyo,  Japan) with a camera adapter and 
sensitivity set on automatic ontrol (CMA-D2, Sony), a 
video timer (VTG-22) and scale marker (IV-600, both 
from For-A-Company,  Tokyo, Japan), a video monitor 
(Picture Monitor  model PM 171T, Ikegami Tsushinki, 
Tokyo, Japan) and a video tape recorder (S-VHS, AG- 
7350, Panasonic, Osaka, Japan). The microscope is 
equipped with 1.0/0.04, 2.5/0.08, 6.3/0.20 and 10/0.25 
planar objectives (Leica, Heerbrugg, Switzerland), which 
allow a magnification of 24, 62, 165 and 240 times, 
respectively, on the monitor. The fluorescence excitation 
filter works at 450-490 nm and the barrier filter at 
515 nm. The NaF  was injected into the antecubital vein 
as a bolus; the dosage was adjusted according to the 
estimated blood volume. At our institution 0.2~).3 ml 
NaF  20% per liter estimated blood volume is used and is 
adequate for visualization of skin capillaries. 
The following parameters of NC were evaluated from 
the videotape [19]: 
- Irregular architecture (capillaries not in one row as 
normal, small areas (< 500 ~tm) with missing capil- 
laries next to areas with clusters of capillaries) 
- Avascular fields (loss of  capillaries in a field of  at least 
500 ~tm) 
- Dilatation of  capillaries (arterial side > 15 ~m, venous 
side > 20 I~m) 
- Giant capillaries (apical diameter > 50 I~m, Fig. 1) 
- NaF images were evaluated for apical halo enlargement 
or "dwar f  hat"  formation, respectively (Fig. 2) [16]. 
Fig. 1 Typical giant capillary of the nailfold in a female patient 
with RP who developed CREST 10 years after NC (×63). 
Rheumatism Association (ARA) [20]. The diagnosis of 
CREST was made when the following criteria were 
fulfilled: calcinosis, Raynaud's phenomenon, oesopha- 
geal dysmotility, sclerodactyly, and telangiectasia n the 
Diagnostic criteria 
The diagnosis of  systemic sclerosis (Scl) was made 
according to the preliminary criteria of  the American 
Fig. 2 a After the intravenous injection of NaF apical halo 
enlargement or "dwarf hat" formation might be seen in patients 
with CTD. b In healthy subjects the cells are surrounded by the 
fluorescent plasma layer and NaF does not pass the narrow 
pericapillary border (×63). 
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presence of anticentromere antibodies. Mixed connec- 
tive tissue disease (MCTD) was diagnosed in the pres- 
ence of symptoms as described by Alarcon-Segovia and 
Cardiel [21]. The diagnoses of SLE and rheumatoid 
arthritis (RA) were based on the diagnostic riteria of 
the ARA. Dermatomyositis (DM) was considered the 
diagnosis when the criteria of Bohan and Peter [22] were 
present, Sj6gren's syndrome was diagnosed when the 
diagnostic riteria from the American-European Con- 
sensus Group were present, including the presence of 
autoantibodies (anti-Ro/SSA, anti-La/SSB or both) [23]. 
Statistical analysis 
Analyses were performed with the statistical software 
package Stat View 5.0. Continuous variables are reported 
as means and categorical variables as percentages. Com- 
parison between groups of patients was done by means of 
unpaired Student's t-test and for categorical variables by 
using Fisher's exact est. A test for logistic regression was 
performed as a means of studying the diagnostic value of 
the different features of NC to predict development of 
CTD. Significance was defined as p < 0.05. 
Results 
Of a total of 1024 patients een with RP between 1992 
and 2002, the results of 968 patients were evaluated for 
the present study; 19 patients with Osler's disease and 37 
patients for whom some data were missing had been 
excluded. In 693 patients, the NaF test was performed in 
addition to conventional NC. In 201 (155 females and 46 
males) patients referred to us because of RP the diag- 
nosis of a CTD had already been made at the time of NC 
due to serological features and the above-mentioned 
criteria. The diagnosis and results of NC from these 201 
patients are shown in Table 1. Microangiopathy was 
defined as being present if at least one of the above- 
mentioned criteria was found. The diagnosis of primary 
RP was made in 459 patients because the following 
criteria were fulfilled: normal findings in NC, negative 
autoantibodies, no signs of a CTD according to the 
ARA criteria, no calcinosis, no oesophageal motility 
disturbances, no sclerodactyly, no telangiectasia and no 
xerostomia. In 308 patients with normal serological 
findings and no clinical signs of a CTD despite RP, we 
found pathological features in NC suspicious for CTD. 
Of these 308 patients with RP and microangiopathy in 
NC, follow-up data were available for 133 patients: 107 
females (mean age: 50.0 years, range: 10-89 years) and 
26 males (mean age: 55.1 years, range: 26-82 years). The 
NaF had been administered in 51 (38.4%) patients. 
After a mean follow-up of 6.5 years (range: 1-15 years), 
109 patients (82%, group 1) had developed a CTD 
according to the above-described criteria, The patient 
characteristics, diagnoses and findings of NC in these 
patients are shown in Table 2, 
The remaining 24 patients (group 2, 19 females, 5 
males, mean age: 45.6 years, range: 21-70) had not 
developed any clinical signs of a CTD and serological 
tests were still negative after a mean follow-up of 
8.5 years (range: 2-15 years). Patient characteristics and 
features of NC are shown in Table 3. There were no 
statistically significant differences in age, duration of RP 
or duration of follow-up in patients who developed a
CTD (group 1) compared to patients who had not 
developed a CTD (group 2) during the follow-up. For 
comparison between the two groups, only patients who 
had not developed a CTD after a follow-up of at least 
6 years had been included: four patients with a follow- 
up of 4 years (two patients), one patient with a follow- 
up of 5 years and one patient with a follow-up of 2 years 
had been excluded from the analysis [2]. The mean fol- 
low-up of these 20 patients was 9.3 years (range: 6- 
15 years). The features and comparison of NC in the 
two groups are shown in Fig. 3. In group 1 significantly 
more giant capillaries (p=0.0001), avascular fields 
(p=0.02) and irregular architecture (p=0.0001) had 
been observed at the initial investigation. Including all 
24 patients the results were almost identical; the same 
features (giant capillaries, avascular fields and irregular 
architecture) had been identified as significantly different 
in the two groups (p < 0.05). 
Furthermore, the presence of giant capillaries or an 
irregular architecture was predictive for the development 
of a CTD (p < 0.005). Only two patients developed SLE 
Table 1 Age, sex and presence 
or absence of pathological Patients 
features in nailfold (n/%) 
capillaroscopy (NC) of 201 
patients with RP, in whom an 
underlying disease had been 
already diagnosed atthe time of 
NC. Scl systemic sclerosis, Scl 93/46.3 
CREST calcinosis, Raynaud's CREST 8/4.0 
phenomenon, oesophageal SLE 29/14.4 
dysfunction, sclerodactyly, MCTD 29/14.4 
telangiecstasia, SLE systemic DM 14/7.0 
lupus erythematosus, MCTD Sj6gren's 9/4.5 
mixed connective tissue disease, syndrome 
DM dermatomyositis, RA RA 19/9.4 
rheumatoid arthritis Total 201 
Diagnosis Age (mean,  Female/male Presence of 
range, years) (%) microangiopathy 
(%) 
Yes No 
52.4 (13-78) 72.0/28.0 83.9 16.1 
62.4 (36-76) 87.5/12.5 87.5 12.5 
39.1 (12~53) 82.8/17.2 37.9 62.1 
50.7 (27-83) 86.2/13.8 65.5 34.5 
52.6 (17-70) 57.1/42.9 57.1 42.9 
52.6 (17~59) 88.9/11. l 44.5 55.5 
50,3 (22-73) 84.2/15.8 31.6 68.4 
51.5 (12-83) 77.1/22.9 60.7 39.3 
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Table 2 Characteristics of 109 patients with RP and pathological 
features in the nailfold capillaroscopy and their diagnosis after a 
mean follow-up of 6.5 years (1-15 years). Scl systemic sclerosis, 
CREST calcinosis, Raynaud's phenomenon, oesophageal dys- 
function, sclerodactyly, telangiecstasia, SLE systemic lupus eryth- 
ematosus, MCTD mixed connective tissue disease, DM 
dermatomyositis 
Diagnosis Patients Age Female/male Duration Giant Dilated Avascular Irregular NaF 
(n) (years) of RP capillaries capillaries fields (%) (%) performed 
(years) (%) (%) (%)/halo (%) 
Scl 46 51.1 (16-75) 80.4/19.6 5.1 (0.5-45) 89.1 89.1 19.5 73 .9  28.3/77.0 
CREST 30 57.1 (10-89) 83.3/16.7 8.4 (0.5-49) 80.0 90.0 30.0 60.0 30.0/89.0 
SLE 2 57.0 (55-59) 100/0 7.0 (1-13) 100 100 50.0 100 100/100 
MCTD 29 52.5 (10-82) 75.9/24.1 8.5 (0.5-40) 62.1 90.0 20.7 58.6 48.3/85.7 
DM 2 65.5 (59-72) 100/0 0.5 100 100 50.0 100 100/100 
Total 109 52.9 (10-89) 88/21 6.9 (0.5-49) 79.8 89.9 23.8 67.0 34.0/81.6 
Table 3 Characteristics of 24 patients with RP and pathological features in the nailfold capillaroscopy who did not develop CTD after a 
mean follow-up of 8.5 years (2-15 years) 
Patients Age Female/male Duration Giant Dilated Avascular Irregular NaF performed 
(n) (years) (%) of RP (years) capillaries capillaries fields (%) (%) (%)/halo (%) 
(%) (%) 
24 45.6 (21-70) 79.2/20.8 6.5 (1-20) 41.7 83.3 4.1 29.2 58.3/85.7 
and DM,  respectively; therefore no conclusions for these 
diseases can be drawn from our data. 
Discussion 
NC has been accepted as one of  the most valuable 
diagnostic tools for the early detection of  CTD,  in par- 
ticular for Scl and CREST [24-26]. In the present study, 
we analysed the features of  NC in patients with RP in 
order to evaluate the predictive value of  pathological 
findings. We found that during the mean follow-up of  
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Fig. 3 Comparison of features of nailfold capillaroscopy in 
patients with RP. In patients who developed a connective tissue 
disease (CTD) during follow-up significantly more giant capillaries 
(p = 0.0001), avascular fields (p= 0.02) and irregular architecture 
(p=0.0001) have been found than in the 20 patients without any 
laboratory or clinical signs of a CTD after a follow-up of at least 
6years (mean follow-up: 9.3 years, range: 6-15years). The 
enlargement of the apical halo after injection of NaF was not 
different in the two groups. 
6.5 years 82% of  patients with RP and pathological 
findings in NC developed a CTD,  mainly Scl, CREST 
and MCTD.  These patients had shown significantly 
more giant capillaries, irregular architecture and avas- 
cular fields in the initial NC than the group who did not 
develop a CTD.  The presence of  giant capillaries and 
irregular architecture in NC were both predictive for the 
development of a CTD in our patient population. 
It  has been shown that patients with CTD,  especially 
with Scl and CREST,  a typical "cap"  formation or 
"lake-l ike" areas can be seen at the apex of  the capillary 
after injection of NaF  as a sign of  disturbed barriers for 
diffusion of  the dye at the capil lary wall and at the outer 
border of  the skin papil la (halo) [17, 27]. In 38.4% of our 
patients with RP, the NaF  test was performed. We 
found a pathological apical diffusion in 81.6% of  pa- 
tients who developed a CTD during the follow-up; 
however, 85.7% of patients without any signs of a CTD 
after a mean follow-up of  8.5 years also showed the 
same halo pattern. F rom our data we can conclude that 
the additional use of  NaF  does not facilitate early 
detection of a CTD.  However,  even when we analyse 
only patients with a fol low-up of  at least 6 years the 
presence of  pathological halo format ion was not pre- 
dictive for CTD.  
Dilated capillaries were a very common but unspecific 
finding in our patient population. They were present in 
over 80% and their presence was not predictive for the 
development of a CTD.  However,  they have been de- 
scribed in CTD,  in acrocyanosis and less pronounced in 
pr imary RP [28, 29]. In CTD dilated capillaries are 
usually not the only pathological feature of  NC, whereas 
in pr imary RP and pr imary acrocyanosis additional 
pathological features such as giant capillaries or avas- 
cular fields are missing. 
It is known that a CTD might develop many years 
after the onset of  RP; therefore, the Allen and Brown 
criteria requiring at least a 2-year history of RP for the 
diagnosis of a pr imary RP have been revised [30]. In our 
analysis the mean duration of  RP at the time of NC was 
6.9 years in the group who developed a CTD and 
6.5 years in the group who did not. In patients who 
developed a CTD during the follow-up, duration of RP 
up to 49 years has been reported. Our data suggest hat 
the duration of  RP is a very poor criterion for identi- 
fying patients at risk for the development of secondary 
RP. 
The mean age was not different in the two patient 
groups, although children and very young adults (age 
between 10 and 21) were only seen in the group who 
developed a CTD during the follow-up. The number 
might be too low for a conclusion, but it suggests that in 
children and young adults with RP and pathological 
capillaries the risk for an underlying disease is higher. 
In 201 patients (77.1% female) the diagnosis of an 
underlying disease had already been made at the time of  
NC. About half of  the patients had been diagnosed with 
a form of Scl; in these patients a microangiopathy in NC 
was present in over 80%. In contrast, only in 37.9% of 
patients with SLE was microangiopathy present. Path- 
ological capillary morphology has been reported in 2-  
90% of SLE patients [10, 31]. This variation in published 
numbers might be due, at least in part, to the definition 
of microangiopathy used by the authors. Furthermore, it 
has been speculated that the presence of microangiop- 
athy might be associated with clinical features, such as 
RP or specific antibodies. Furtado et al. [32] found a 
significant association between microangiopathy in SLE 
and RP, and similar findings were reported by Caspary 
et al. [33]; however, in a study of 51 patients with SLE 
Bongard et ai. [34] found no correlation between 
abnormal capiUaroscopic findings and RP. In our study, 
only patients with RP were included, which might be one 
reason for the rather high incidence of microangiopathy 
in our group. A higher incidence of microangiopathy 
among SLE patients with positive anticardiolipin and 
anti-Ul r ibonucleoprotein antibodies has been demon- 
strated, suggesting direct damage to the endothelium by 
these antibodies [32, 34]. However, specific autoanti- 
bodies in Scl patients (i.e. anti-Scl-70 and anticardiolipin 
antibody) do not seem directly linked to the expression 
of  a singular capil laroscopic pattern [35]. 
In conclusion, in patients presenting with RP the 
presence of  either giant capillaries, avascular fields or 
irregular architecture in NC is predictive for the devel- 
opment of  a CTD,  mainly scleroderma, CREST and 
MCTD. NC may not be a valuable diagnostic tool in 
SLE, but it might be helpful in identifying a subgroup of 
patients with different evolution and prognosis of the 
disease. The durat ion of  RP was not a criterion for the 
risk of future development of  CTD. Despite the fact that 
in Scl a specific diffusion pattern after NaF  injection 
might be present, the additional use of NaF  does not 
facilitate early detection of  a CTD. 
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Take hone message 
In patients with RP and negative serological tests, the 
presence of  giant capillaries, avascular fields or irregular 
architecture in NC is predictive for the development of a 
CTD, mainly scleroderma, CREST and MCTD.  Based 
on our data the duration of RP is not a criterion for the 
risk of future development of CTD. 
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